Log In
BCIQ
Print this Print this
 

Aducanumab (BIIB037)

  Manage Alerts
Collapse Summary General Information
Company Neurimmune Holding AG
DescriptionHuman recombinant anti-beta amyloid mAb
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/10/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today